title: Measurement of 5-methoxypsoralen and 8-methoxypsoralen in saliva of PUVA patients as a noninvasive, clinically relevant alternative to monitoring in blood.
abstract: BACKGROUND
  Monitoring of psoralen concentration and time-course in PUVA patients is vital for efficient PUVA therapy. Blood sampling is invasive and labour-intensive and thus unsuited for routine use and repeat measurements over the course of therapy.
  
  
  OBJECTIVE
  Psoralen pharmacokinetics in saliva were investigated and validated as a noninvasive, simple and biologically relevant alternative to measurements in blood.
  
  
  METHODS
  The time-course of psoralen concentration was measured in saliva and serum of volunteers and patients receiving PUVA or extracorporeal photopheresis therapy. The samples were analysed by high-performance liquid chromatography. Three commonly used oral psoralen preparations were tested: Psoraderm5 (5-methoxypsoralen; 5-MOP), Meladinine and Oxsoralen (both 8-methoxypsoralen; 8-MOP).
  
  
  RESULTS
  The pharmacokinetic parameter Cmax in saliva averaged 10% (range 6-20%) of the serum values for 8-MOP, and < or = 4% for 5-MOP. These concentrations correspond to the therapeutically relevant, non-albumin-bound fraction of psoralen in serum that is available to diffuse into the tissues. The parameter tmax in saliva and serum coincided, indicating that psoralens diffuse rapidly between the two compartments.
  
  
  CONCLUSIONS
  Monitoring of psoralens in saliva is a valuable, noninvasive alternative to measurements in serum, suitable for routine use. A series of five or six saliva samples is sufficient to determine tmax in a patient beginning photochemotherapy. To determine Cmax, three independent saliva measurements at t = tmax are recommended.
authors.affiliation: Department of Dermatology, University Hospital of Zürich, Switzerland. shephard@derm.unizh.ch
authors.forename: S E
authors.initials: SE
authors.lastname: Shephard
authors.forename: M
authors.initials: M
authors.lastname: Zogg
authors.forename: G
authors.initials: G
authors.lastname: Burg
authors.forename: R G
authors.initials: RG
authors.lastname: Panizzon
mesh_terms: D000078223:5-Methoxypsoralen; D000328:Adult; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008730:Methoxsalen / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics*; D008875:Middle Aged; D009994:Osmolar Concentration; D011701:PUVA Therapy; D012016:Reference Values; D012463:Saliva / Q000378:metabolism*; D012751:Sezary Syndrome / Q000188:drug therapy / Q000378:metabolism; D013997:Time Factors
chemical_list: D000078223:5-Methoxypsoralen; D008730:Methoxsalen